Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06601049 · ClinicalTrials.gov registry record · NA
Effectiveness of ResArgin on Adult's Body Composition and Health
A NA study of Weight Loss, sponsored by Dr. Heather Hausenblaus.
- Active
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06601049: Active NA study of Weight Loss, sponsored by Dr. Heather Hausenblaus.
NCT06601049 is a NA study of Weight Loss that is active but no longer recruiting, run by Dr. Heather Hausenblaus. The registered enrollment target is 60 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06601049, a NA study of Weight Loss, is active but no longer recruiting, sponsored by Dr. Heather Hausenblaus.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if the supplement ResArgin (a reservatrol-based supplement) works to slow down muscle loss during a period of fat loss. Other related health outcomes such as sleep, mood, and activity will be assessed. The main questions it aims to answer are: Does ResArgin improve muscle loss? Does ResArgin improve sleep quality, activity, mood, and body satisfaction. Researchers will compare ResArgin to a placebo (a look-alike substance that contains no active ingredients) to see if ResArgin works to improve muscle loss and related health outcomes. Participants will: Take ResArgin or the Placebo every day for 3 months Assessment will occur at Baseline, Day 30, Day 60, and Day 90. Participants will complete a daily diary of their mood and health.
Primary Outcome
This will be assessed objectively by a trained health professional.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT ResArgin
Study Locations (1)
Florida
- Jacksonville University - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2025-02-15 |
| Phase | NA |
What the registry record for NCT06601049 still lists
NCT06601049 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which ResArgin is the first listed.
NCT06601049 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06601049 about?
NCT06601049 is a clinical study titled "Effectiveness of ResArgin on Adult's Body Composition and Health". The goal of this clinical trial is to learn if the supplement ResArgin (a reservatrol-based supplement) works to slow down muscle loss during a period of fat loss. Other related health outcomes such as sleep, mood, and activity will be assessed. The main questions it aims to answer are: Does ResArg...
What is the current status of trial NCT06601049?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-08-15. Estimated completion is 2025-02-15.
What conditions does trial NCT06601049 study?
This clinical trial studies the following conditions: Weight Loss.
What interventions are being tested in trial NCT06601049?
The interventions under investigation include: ResArgin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06601049?
This trial is sponsored by Dr. Heather Hausenblaus, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06601049 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06601049's enrollment target sits among peer trials
60 67th of 116 higher than 42 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
Circadian Time Restricted Eating
RECRUITING · NA
-
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI